Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRTX NASDAQ:GNMX NYSE:JATT NASDAQ:ZIVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRTXCortexyme$1.60-0.6%$1.68$1.78▼$40.66$48.24M1.4620,672 shs349,672 shsGNMXAevi Genomic Medicine$0.17$0.17$0.11▼$0.35$12.89M1.133.16 million shs2.95 million shsJATTJATT Acquisition$1.99-2.9%$1.77$7.80▼$12.38$34.33MN/A41,322 shs787,641 shsZIVOZIVO Bioscience$13.01+0.1%$14.69$9.97▼$22.15$49.66MN/A1,077 shs661 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRTXCortexyme0.00%+1.90%0.00%+23.85%+119.05%GNMXAevi Genomic Medicine0.00%0.00%0.00%0.00%0.00%JATTJATT Acquisition+7.89%+1.49%+18.50%+81.42%-47.16%ZIVOZIVO Bioscience+0.08%+0.08%-24.36%-8.51%-7.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRTXCortexyme$1.60-0.6%$1.68$1.78▼$40.66$48.24M1.4620,672 shs349,672 shsGNMXAevi Genomic Medicine$0.17$0.17$0.11▼$0.35$12.89M1.133.16 million shs2.95 million shsJATTJATT Acquisition$1.99-2.9%$1.77$7.80▼$12.38$34.33MN/A41,322 shs787,641 shsZIVOZIVO Bioscience$13.01+0.1%$14.69$9.97▼$22.15$49.66MN/A1,077 shs661 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRTXCortexyme0.00%+1.90%0.00%+23.85%+119.05%GNMXAevi Genomic Medicine0.00%0.00%0.00%0.00%0.00%JATTJATT Acquisition+7.89%+1.49%+18.50%+81.42%-47.16%ZIVOZIVO Bioscience+0.08%+0.08%-24.36%-8.51%-7.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRTXCortexyme 0.00N/AN/AN/AGNMXAevi Genomic Medicine 0.00N/AN/AN/AJATTJATT Acquisition 0.00N/AN/AN/AZIVOZIVO Bioscience 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRTXCortexymeN/AN/AN/AN/A$3.97 per shareN/AGNMXAevi Genomic MedicineN/AN/AN/AN/A$0.12 per shareN/AJATTJATT AcquisitionN/AN/A$0.07 per share27.08($0.53) per shareN/AZIVOZIVO Bioscience$15.85K3,133.07N/AN/A($0.81) per share-16.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRTXCortexyme-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/AGNMXAevi Genomic Medicine-$30.77M-$0.50N/A∞N/AN/A-898.31%-286.73%N/AJATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/AZIVOZIVO Bioscience-$7.78M-$2.58N/A∞N/AN/AN/A-2,240.92%11/12/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRTXCortexymeN/AN/AN/AN/AN/AGNMXAevi Genomic MedicineN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/AZIVOZIVO BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRTXCortexymeN/A9.929.92GNMXAevi Genomic MedicineN/A0.650.65JATTJATT AcquisitionN/A0.150.15ZIVOZIVO BioscienceN/A0.170.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRTXCortexyme63.18%GNMXAevi Genomic Medicine7.03%JATTJATT Acquisition47.97%ZIVOZIVO Bioscience12.83%Insider OwnershipCompanyInsider OwnershipCRTXCortexyme27.90%GNMXAevi Genomic Medicine43.80%JATTJATT Acquisition20.00%ZIVOZIVO Bioscience48.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRTXCortexyme5530.15 million21.74 millionNot OptionableGNMXAevi Genomic Medicine1477.71 millionN/AOptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionableZIVOZIVO Bioscience103.82 million2.91 millionNot OptionableGNMX, ZIVO, CRTX, and JATT HeadlinesRecent News About These CompaniesZIVO Bioscience releases letter to shareholdersSeptember 14, 2025 | wattagnet.comWZIVO Bioscience (NASDAQ:ZIVO) Shares Pass Above 50 Day Moving Average - Here's What HappenedSeptember 11, 2025 | marketbeat.comZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic BusinessesSeptember 10, 2025 | businesswire.comZIVO Bioscience (NASDAQ:ZIVO) Stock Passes Above 50 Day Moving Average - Here's WhyAugust 30, 2025 | marketbeat.comZIVO Bioscience (NASDAQ:ZIVO) Stock Price Crosses Above 50-Day Moving Average - Should You Sell?August 22, 2025 | marketbeat.comZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in PoultryJune 20, 2025 | businesswire.comUniversity of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryMay 7, 2025 | finance.yahoo.comUniversity of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryMay 6, 2025 | businesswire.comZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in PoultryFebruary 6, 2025 | businesswire.comZivo Bioscience issues new shares, raises $1.5 millionJanuary 28, 2025 | msn.comTuesday's Insider Activity: Top Buys and Sells in US Stocks RevealedJanuary 1, 2025 | investing.comZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian InfluenzaDecember 20, 2024 | businesswire.comZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023March 18, 2024 | investorplace.comHarmony Biosciences HoldingsMarch 4, 2024 | forbes.comRegencell Bioscience Holdings Ltd RGCFebruary 1, 2024 | morningstar.comMZIVO Bioscience Announces Uplisting to OTCQB MarketJanuary 29, 2024 | finance.yahoo.comIdeaya BiosciencesJanuary 18, 2024 | forbes.comDare Bioscience Inc DAREJanuary 14, 2024 | morningstar.comMZivo Bioscience Inc (ZIVO) USD0.001November 11, 2023 | hl.co.ukZivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72November 1, 2023 | msn.comZivo Bioscience Inc ZIVONovember 1, 2023 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNMX, ZIVO, CRTX, and JATT Company DescriptionsCortexyme NASDAQ:CRTX$1.60 -0.01 (-0.62%) As of 09/19/2025Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Aevi Genomic Medicine NASDAQ:GNMXAevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.JATT Acquisition NYSE:JATT$1.99 -0.06 (-2.93%) As of 09/19/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.ZIVO Bioscience NASDAQ:ZIVO$13.01 +0.01 (+0.08%) As of 09/19/2025 03:25 PM EasternZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
